{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T14:45:09Z","timestamp":1793112309455,"version":"4.5.0"},"reference-count":206,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["2632023TD05"],"award-info":[{"award-number":["2632023TD05"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20210426"],"award-info":[{"award-number":["BK20210426"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["[2022] 3-16-190"],"award-info":[{"award-number":["[2022] 3-16-190"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018592","name":"\u201c333 Project\u201d of Jiangsu Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018592","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373815"],"award-info":[{"award-number":["82373815"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073795"],"award-info":[{"award-number":["82073795"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82104097"],"award-info":[{"award-number":["82104097"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82372113"],"award-info":[{"award-number":["82372113"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.jconrel.2024.09.012","type":"journal-article","created":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T20:42:00Z","timestamp":1726605720000},"page":"346-365","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"special_numbering":"C","title":["Amyloid-\u03b2-targeting immunotherapies for Alzheimer's disease"],"prefix":"10.1016","volume":"375","author":[{"given":"Yi","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaofei","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjie","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixin","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaqing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2024.09.012_bb0005","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1002\/alz.13016","article-title":"2023 Alzheimer's disease facts and figures","volume":"19","year":"2023","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0010","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1038\/s41401-020-00565-5","article-title":"New therapeutics beyond amyloid-\u03b2 and tau for the treatment of Alzheimer's disease","volume":"42","author":"Zhang","year":"2021","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0015","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1039\/C6CS00731G","article-title":"Towards an understanding of amyloid-\u03b2 oligomers: characterization, toxicity mechanisms, and inhibitors","volume":"46","author":"Lee","year":"2017","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0020","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s13311-022-01201-2","article-title":"Disease-modifying therapies for Alzheimer\u2019s disease: more questions than answers","volume":"19","author":"Golde","year":"2022","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0025","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s40035-022-00292-3","article-title":"Immunotherapy for Alzheimer's disease: targeting \u03b2-amyloid and beyond","volume":"11","author":"Song","year":"2022","journal-title":"Transl. Neurodegener."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0030","doi-asserted-by":"crossref","first-page":"E1295","DOI":"10.1212\/WNL.0000000000006277","article-title":"Dominantly inherited Alzheimer, longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease","volume":"91","author":"McDade","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0035","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1001\/jamaneurol.2020.4857","article-title":"Findings of efficacy, safety, and biomarker outcomes of Atabecestat in preclinical Alzheimer disease a truncated randomized phase 2b\/3 clinical trial","volume":"78","author":"Sperling","year":"2021","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0040","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3390\/pharmaceutics13122014","article-title":"Current and emerging strategies for enhancing antibody delivery to the brain","volume":"13","author":"Bajracharya","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0045","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1002\/alz.13684","article-title":"Do anti-A\u03b2 monoclonal antibodies lower brain plaques in Alzheimer patients through microglia activation?","volume":"20","author":"Pomara","year":"2024","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0050","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1093\/brain\/awad188","article-title":"Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics","volume":"146","author":"Hampel","year":"2023","journal-title":"Brain"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0055","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejphar.2019.172415","article-title":"Trafficking and proteolytic processing of amyloid precursor protein and secretases in Alzheimer\u2019s disease development: an up-to-date review","volume":"856","author":"Yuksel","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0060","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1515\/revneuro-2017-0063","article-title":"Amyloid toxicity in Alzheimer's disease","volume":"29","author":"Reiss","year":"2018","journal-title":"Rev. Neurosci."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0065","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3389\/fnagi.2022.870517","article-title":"Impact of anti-amyloid-\u03b2 monoclonal antibodies on the pathology and clinical profile of Alzheimer\u2019s disease: a focus on aducanumab and lecanemab","volume":"14","author":"Shi","year":"2022","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0070","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jconrel.2017.05.013","article-title":"Multifunctional liposomes delay phenotype progression and prevent memory impairment in a presymptomatic stage mouse model of Alzheimer disease","volume":"258","author":"Mancini","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0075","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/s41593-018-0238-6","article-title":"Propagation and spread of pathogenic protein assemblies in neurodegenerative diseases","volume":"21","author":"Jucker","year":"2018","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0080","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/ana.24270","article-title":"Amyloid-\u03b2 efflux from the central nervous system into the plasma","volume":"76","author":"Roberts","year":"2014","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0085","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/s41593-018-0234-x","article-title":"The role of brain vasculature in neurodegenerative disorders","volume":"21","author":"Sweeney","year":"2018","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0090","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1312889","article-title":"Solanezumab study, phase 3 trials of solanezumab for mild-to-moderate Alzheimer\u2019s disease","volume":"370","author":"Doody","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0095","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/s41591-021-01369-8","article-title":"A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer\u2019s disease","volume":"27","author":"Salloway","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0100","doi-asserted-by":"crossref","first-page":"197","DOI":"10.14283\/jpad.2022.30","article-title":"Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease","volume":"9","author":"Haeberlein","year":"2022","journal-title":"JPAD-J. Prev. Alzheimers Dis."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0105","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Skovronsky, donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"Jama"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0110","first-page":"1631","article-title":"Lecanemab in early Alzheimer\u2019s disease","volume":"388","author":"Brenman","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0115","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/bmj.p1580","article-title":"Alzheimer's disease: lecanemab gets full FDA approval and black box safety warning","volume":"382","author":"Mahase","year":"2023","journal-title":"Bmj"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0120","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1056\/NEJMp2111320","article-title":"Controversy and progress in Alzheimer\u2019s disease - FDA approval of aducanumab","volume":"385","author":"Rabinovici","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0125","doi-asserted-by":"crossref","first-page":"38825","DOI":"10.1074\/jbc.R111.288308","article-title":"Pyroglutamate amyloid-\u03b2 (A\u03b2): a hatchet man in Alzheimer disease","volume":"286","author":"Jawhar","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0130","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1038\/s41380-021-01409-2","article-title":"Pyroglutamate A\u03b2 cascade as drug target in Alzheimer\u2019s disease","volume":"27","author":"Bayer","year":"2022","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0135","doi-asserted-by":"crossref","first-page":"562","DOI":"10.2214\/AJR.22.28461","article-title":"Amyloid-related imaging abnormalities: an update","volume":"220","author":"Roytman","year":"2023","journal-title":"Am. J. Roentgenol."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0140","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1474-4422(12)70015-7","article-title":"Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis","volume":"11","author":"Sperling","year":"2012","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0145","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3389\/fnins.2014.00235","article-title":"New roles for fc receptors in neurodegeneration-the impact on immunotherapy for Alzheimer\u2019s disease","volume":"8","author":"Fuller","year":"2014","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2024.102192","article-title":"Passive immunotherapy for Alzheimer\u2019s disease","volume":"94","author":"Guo","year":"2024","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0155","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.cell.2019.09.001","article-title":"Alzheimer disease: an update on pathobiology and treatment strategies","volume":"179","author":"Long","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0160","doi-asserted-by":"crossref","first-page":"7333","DOI":"10.1038\/s41467-022-34538-5","article-title":"Experimental evidence for temporal uncoupling of brain A\u03b2 deposition and neurodegenerative sequelae","volume":"13","author":"Rother","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0165","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1126\/science.adj9255","article-title":"Immunotherapies for Alzheimer\u2019s disease","volume":"382","author":"Golde","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0170","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.jalz.2015.06.1884","article-title":"A fresh perspective from immunologists and vaccine researchers: active vaccination strategies to prevent and reverse Alzheimer\u2019s disease","volume":"11","author":"Agadjanyan","year":"2015","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0175","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/pep2.24289","article-title":"Current peptide vaccine and immunotherapy approaches against Alzheimer's disease","volume":"115","author":"Parrocha","year":"2023","journal-title":"Pept. Sci."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0180","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41582-018-0013-z","article-title":"Tau-targeting therapies for Alzheimer disease","volume":"14","author":"Congdon","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0185","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/22124","article-title":"Immunization with amyloid-\u03b2 attenuates Alzheimer disease-like pathology in the PDAPP mouse","volume":"400","author":"Schenk","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0190","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1101\/cshperspect.a024331","article-title":"Antibody therapeutics targeting A\u03b2 and tau","volume":"7","author":"Gallardo","year":"2017","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0195","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/jnc.13608","article-title":"A retrospective analysis of the Alzheimer\u2019s disease vaccine progress - the critical need for new development strategies","volume":"137","author":"Marciani","year":"2016","journal-title":"J. Neurochem."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0200","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.3233\/JAD-150376","article-title":"Two phase 2 multiple ascending-dose studies of Vanutide Cridificar (ACC-001) and QS-21 adjuvant in mild-to-moderate Alzheimer\u2019s disease","volume":"51","author":"Pasquier","year":"2016","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0205","doi-asserted-by":"crossref","first-page":"9323","DOI":"10.1523\/JNEUROSCI.0293-11.2011","article-title":"The second-generation active A\u03b2 immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects","volume":"31","author":"Wiessner","year":"2011","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0210","doi-asserted-by":"crossref","first-page":"4923","DOI":"10.1523\/JNEUROSCI.4672-12.2013","article-title":"Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer\u2019s disease: prelude to a clinical trial","volume":"33","author":"Davtyan","year":"2013","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0215","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1371\/journal.pone.0154757","article-title":"Meta-analysis on randomized controlled trials of vaccines with QS-21 or ISCOMATRIX adjuvant: safety and tolerability","volume":"11","author":"Bigaeva","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0220","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.trci.2017.03.005","article-title":"UB-311, a novel UBITh amyloid beta peptide vaccine for mildAlzheimer'sdisease","volume":"3","author":"Wang","year":"2017","journal-title":"Alzheimer's & Dementia (New York, N. Y.)"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0225","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13195-018-0340-8","article-title":"Safety, tolerability and immunogenicity of an active anti-A\u03b2<sub>40<\/sub> vaccine (ABvac40) in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase I trial","volume":"10","author":"Lacosta","year":"2018","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0230","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1126\/science.abm7285","article-title":"Cryo-EM structures of amyloid-\u03b2 42 filaments from human brains","volume":"375","author":"Yang","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0235","doi-asserted-by":"crossref","first-page":"9810","DOI":"10.1073\/pnas.0703137104","article-title":"Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice","volume":"104","author":"Muhs","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0240","doi-asserted-by":"crossref","first-page":"15595","DOI":"10.1073\/pnas.1001740107","article-title":"Stabilization of neurotoxic Alzheimer amyloid-\u03b2 oligomers by protein engineering","volume":"107","author":"Sandberg","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0245","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/s13311-022-01236-5","article-title":"The current landscape of prevention trials in dementia","volume":"19","author":"Lee","year":"2022","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0250","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ymthe.2016.10.002","article-title":"Comparison of efficacy of preventive and therapeutic vaccines targeting the N terminus of \u03b2-amyloid in an animal model of Alzheimer\u2019s disease","volume":"25","author":"Petrushina","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0255","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40035-020-00195-1","article-title":"Peripheral clearance of brain-derived A\u03b2 in Alzheimer's disease: pathophysiology and therapeutic perspectives","volume":"9","author":"Cheng","year":"2020","journal-title":"Transl. Neurodegener."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0260","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1093\/brain\/awab465","article-title":"Next-generation antibody-based therapies in neurology","volume":"145","author":"Ruck","year":"2022","journal-title":"Brain"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0265","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.addr.2019.11.009","article-title":"The blood-brain barrier: physiology and strategies for drug delivery","volume":"165-166","author":"Pandit","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0270","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.isci.2023.108132","article-title":"Exit pathways of therapeutic antibodies from the brain and retention strategies","volume":"26","author":"Schellhammer","year":"2023","journal-title":"iScience"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2024.115219","article-title":"Interactions between nanoparticles and pathological changes of vascular in Alzheimer\u2019s disease","volume":"207","author":"Lei","year":"2024","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0280","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adj5958","article-title":"Nasal tau immunotherapy clears intracellular tau pathology and improves cognitive functions in aged tauopathy mice","volume":"16","author":"Gaikwad","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0285","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2309221120","article-title":"Nasal administration of anti-CD3 monoclonal antibody ameliorates disease in a mouse model of Alzheimer's disease","volume":"120","author":"Lopes","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0290","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adq6489","article-title":"A nose for tau","volume":"16","author":"Meftah","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0295","article-title":"Microenvironment remodeling micelles for Alzheimer\u2019s disease therapy by early modulation of activated microglia","volume":"6","author":"Lu","year":"2019","journal-title":"Adv. Sci. (Weinh)"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0300","article-title":"Multifunctional nanostructure RAP-RL rescues Alzheimer\u2019s cognitive deficits through remodeling the neurovascular unit","volume":"8","author":"Zhang","year":"2021","journal-title":"Adv. Sci. (Weinh)"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0305","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.2147\/IJN.S239608","article-title":"Transferrin-modified osthole PEGylated liposomes travel the blood-brain barrier and mitigate Alzheimer\u2019s disease-related pathology in APP\/PS-1 mice","volume":"15","author":"Kong","year":"2020","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0310","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1080\/10717544.2018.1461955","article-title":"Curcumin-loaded PLGA-PEG nanoparticles conjugated with B6 peptide for potential use in Alzheimer\u2019s disease","volume":"25","author":"Fan","year":"2018","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0315","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.201909999","article-title":"Endo\/lysosome-escapable delivery depot for improving BBB transcytosis and neuron targeted therapy of Alzheimer\u2019s disease","volume":"30","author":"Cai","year":"2020","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0320","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.jconrel.2020.01.039","article-title":"A dual-ligand fusion peptide improves the brain-neuron targeting of nanocarriers in Alzheimer\u2019s disease mice","volume":"320","author":"Guo","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0325","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/s12951-024-02543-z","article-title":"A\u03b2(42) and ROS dual-targeted multifunctional nanocomposite for combination therapy of Alzheimer's disease","volume":"22","author":"Zhang","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0330","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ijbiomac.2020.06.058","article-title":"Self- assembled lactoferrin-conjugated linoleic acid micelles as an orally active targeted nanoplatform for Alzheimer\u2019s disease","volume":"162","author":"Agwa","year":"2020","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0335","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abf9180","article-title":"Targeting Alzheimer\u2019s disease with multimodal polypeptide-based nanoconjugates","volume":"7","author":"Duro-Castano","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0340","doi-asserted-by":"crossref","first-page":"7594","DOI":"10.1073\/pnas.0702170104","article-title":"Targeted delivery of proteins across the blood-brain barrier","volume":"104","author":"Spencer","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0345","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202101748","article-title":"\u201ccascaded rocket\u201d nanosystems with spatiotemporal separation for triple-synergistic therapy of Alzheimer\u2019s disease","volume":"11","author":"Liu","year":"2022","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0350","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abc7031","article-title":"Blood-brain barrier-penetrating siRNA nanomedicine for Alzheimer\u2019s disease therapy","volume":"6","author":"Zhou","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0355","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1021\/acsnano.3c09715","article-title":"Mannose-integrated nanoparticle hitchhike glucose transporter 1 recycling to overcome various barriers of oral delivery for Alzheimer\u2019s disease therapy","volume":"18","author":"Lei","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0360","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jconrel.2015.02.012","article-title":"Enhanced glutathione PEGylated liposomal brain delivery of an anti-amyloid single domain antibody fragment in a mouse model for Alzheimer's disease","volume":"203","author":"Rotman","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0365","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.addr.2022.114539","article-title":"Ultrasound-mediated blood-brain barrier opening: an effective drug delivery system for theranostics of brain diseases","volume":"190","author":"Wang","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0370","doi-asserted-by":"crossref","first-page":"46689","DOI":"10.1038\/srep46689","article-title":"Characterization of different microbubbles in assisting focused ultrasound-induced blood-brain barrier opening","volume":"7","author":"Wu","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0375","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1371\/journal.pone.0010549","article-title":"Antibodies targeted to the brain with image-guided focused ultrasound reduces amyloid-\u03b2 plaque load in the TgCRND8 mouse model of Alzheimer\u2019s disease","volume":"5","author":"Jordao","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0380","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40035-022-00333-x","article-title":"Enhanced delivery of a low dose of aducanumab via FUS in 5xFAD mice, an AD model","volume":"11","author":"Kong","year":"2022","journal-title":"Transl. Neurodegener."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0385","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.jconrel.2021.06.037","article-title":"Focused ultrasound with anti-pGlu3 A\u03b2 enhances efficacy in Alzheimer's disease-like mice <i>via<\/i> recruitment of peripheral immune cells","volume":"336","author":"Sun","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0390","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1056\/NEJMoa2308719","article-title":"Ultrasound blood-brain barrier opening and aducanumab in Alzheimer\u2019s disease","volume":"390","author":"Rezai","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0395","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13195-021-00809-4","article-title":"A comparative study of the effects of Aducanumab and scanning ultrasound on amyloid plaques and behavior in the APP23 mouse model of Alzheimer disease","volume":"13","author":"Leinenga","year":"2021","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0400","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jconrel.2019.07.023","article-title":"Safety and efficacy of focused ultrasound induced blood-brain barrier opening, an integrative review of animal and human studies","volume":"309","author":"Meng","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0405","doi-asserted-by":"crossref","first-page":"3989","DOI":"10.7150\/thno.21630","article-title":"Acute inflammatory response following increased blood-brain barrier permeability induced by focused ultrasound is dependent on microbubble dose","volume":"7","author":"McMahon","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0410","doi-asserted-by":"crossref","first-page":"E75","DOI":"10.1073\/pnas.1614777114","article-title":"Disrupting the blood-brain barrier by focused ultrasound induces sterile inflammation","volume":"114","author":"Kovacs","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0415","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: a mechanistic review of the pipeline","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0420","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/s41573-021-00139-y","article-title":"Strategies for delivering therapeutics across the blood-brain barrier","volume":"20","author":"Terstappen","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0425","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.neuron.2015.11.024","article-title":"Discovery of novel blood-brain barrier targets to enhance brain uptake of therapeutic antibodies","volume":"89","author":"Zuchero","year":"2016","journal-title":"Neuron"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0430","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1146\/annurev-pharmtox-010814-124852","article-title":"Targeting receptor-mediated transport for delivery of biologics across the blood-brain barrier","volume":"55","author":"Lajoie","year":"2015","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0435","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nrneurol.2017.188","article-title":"Blood\u2013brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders","volume":"14","author":"Sweeney","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0440","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41598-017-17358-2","article-title":"Pharmacokinetics, biodistribution and brain retention of a bispecific antibody-based PET radioligand for imaging of amyloid-\u03b2","volume":"7","author":"Sehlin","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0445","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40035-020-00214-1","article-title":"SPECT imaging of distribution and retention of a brain-penetrating bispecific amyloid-\u03b2 antibody in a mouse model of Alzheimer's disease","volume":"9","author":"Gustavsson","year":"2020","journal-title":"Transl. Neurodegener."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0450","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13195-023-01236-3","article-title":"Long-term effects of immunotherapy with a brain penetrating A\u03b2 antibody in a mouse model of Alzheimer's disease","volume":"15","author":"Gustavsson","year":"2023","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0455","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/ncomms10759","article-title":"Antibody-based PET imaging of amyloid beta in mouse models of Alzheimer's disease","volume":"7","author":"Sehlin","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0460","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1080\/19420862.2023.2261509","article-title":"Delivery of the Brainshuttle\u2122 amyloid-beta antibody fusion trontinemab to non-human primate brain and projected efficacious dose regimens in humans","volume":"15","author":"Grimm","year":"2023","journal-title":"mAbs"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0465","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.neuron.2013.10.061","article-title":"Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle","volume":"81","author":"Niewoehner","year":"2014","journal-title":"Neuron"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0470","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.omtm.2020.08.014","article-title":"Tetravalent bispecific tandem antibodies improve brain exposure and efficacy in an amyloid transgenic mouse model","volume":"19","author":"Do","year":"2020","journal-title":"Mol.Ther.-Methods Clin. Dev."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0475","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12987-021-00257-0","article-title":"Brain pharmacokinetics of two BBB penetrating bispecific antibodies of different size","volume":"18","author":"Faresj\u00f6","year":"2021","journal-title":"Fluids Barriers CNS"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0480","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/bit.22576","article-title":"IgG-single chain Fv fusion protein therapeutic for Alzheimer\u2019s disease: expression in CHO cells and pharmacokinetics and brain delivery in the Rhesus monkey","volume":"105","author":"Boado","year":"2010","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0485","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jconrel.2019.01.005","article-title":"Modulating the antibody density changes the uptake and transport at the blood-brain barrier of both transferrin receptor-targeted gold nanoparticles and liposomal cargo","volume":"295","author":"Johnsen","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0490","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.cell.2019.02.030","article-title":"Insulin receptor associates with promoters genome-wide and regulates gene expression","volume":"177","author":"Hancock","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0495","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.neuropharm.2016.03.014","article-title":"Antibody therapies in CNS diseases","volume":"120","author":"Freskg\u00e5rd","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0500","doi-asserted-by":"crossref","first-page":"13272","DOI":"10.1096\/fj.202000610RR","article-title":"Brain delivery of biologics using a cross-species reactive transferrin receptor 1 VNAR shuttle","volume":"34","author":"Sehlin","year":"2020","journal-title":"FASEB J."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0505","doi-asserted-by":"crossref","first-page":"5489","DOI":"10.1016\/j.biomaterials.2011.04.020","article-title":"The binding affinity of anti-A\u03b21-42 MAb-decorated nanoliposomes to A\u03b21-42 peptides <i>in vitro<\/i> and to amyloid deposits in post-mortem tissue","volume":"32","author":"Canovi","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0510","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.7150\/thno.30649","article-title":"Using near-infrared enhanced thermozyme and scFv dual-conjugated Au nanorods for detection and targeted photothermal treatment of Alzheimer's disease","volume":"9","author":"Liu","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0515","doi-asserted-by":"crossref","first-page":"4919","DOI":"10.2147\/IJN.S240953","article-title":"Multifunctional superparamagnetic iron oxide nanoparticles conjugated with A\u03b2 oligomer-specific scFv antibody and class A scavenger receptor activator show early diagnostic potentials for Alzheimer\u2019s disease","volume":"15","author":"Liu","year":"2020","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0520","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12951-020-00723-1","article-title":"Superparamagnetic iron oxide nanoparticles conjugated with A\u03b2 oligomer-specific scFv antibody and class A scavenger receptor activator show therapeutic potentials for Alzheimer\u2019s disease","volume":"18","author":"Liu","year":"2020","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0525","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201807965","article-title":"Magnetite\/ceria nanoparticle assemblies for extracorporeal cleansing of amyloid-\u03b2 in Alzheimer\u2019s disease","volume":"31","author":"Kim","year":"2019","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0530","doi-asserted-by":"crossref","first-page":"6729","DOI":"10.1021\/acsnano.9b09991","article-title":"Dual-sensitive nanomicelles enhancing systemic delivery of therapeutically active antibodies specifically into the brain","volume":"14","author":"Xie","year":"2020","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0535","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1093\/jpp\/rgaa068","article-title":"Anti-A\u03b2-scFv-loaded polymeric nano-micelles with enhanced plasma stability","volume":"73","author":"Sotoudegan","year":"2021","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0540","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12951-023-01772-y","article-title":"Peripheral administration of nanomicelle-encapsulated anti-A\u03b2 oligomer fragment antibody reduces various toxic A\u03b2 species in the brain","volume":"21","author":"Amano","year":"2023","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0545","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jconrel.2014.04.010","article-title":"Engineering theranostic nanovehicles capable of targeting cerebrovascular amyloid deposits","volume":"185","author":"Agyare","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0550","first-page":"14","article-title":"Multivalent nanobody conjugate with rigid, reactive oxygen species scavenging scaffold for multi-target therapy of Alzheimer\u2019s disease","volume":"35","author":"Zhao","year":"2023","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0555","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/nrd1632","article-title":"Recent advances with liposomes as pharmaceutical carriers","volume":"4","author":"Torchilin","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0560","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.addr.2020.09.003","article-title":"When liposomes met antibodies: drug delivery and beyond","volume":"154-155","author":"Di","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0565","article-title":"Site-selective lysine acetylation of human immunoglobulin G for immunoliposomes and bispecific antibody complexes","volume":"10","author":"Yuan","year":"2022","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0570","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1039\/D1BM01218E","article-title":"A novel anti-tumor\/anti-tumor-associated fibroblast\/anti-mPEG tri-specific antibody to maximize the efficacy of mPEGylated nanomedicines against fibroblast-rich solid tumor","volume":"10","author":"Chen","year":"2021","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0575","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.addr.2020.07.002","article-title":"Liposomes: advancements and innovation in the manufacturing process","volume":"154","author":"Shah","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0580","first-page":"349","article-title":"The appliances and prospects of aurum nanomaterials in biodiagnostics, imaging, drug delivery and combination therapy","volume":"14","author":"Yang","year":"2019","journal-title":"Asian J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0585","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.bios.2020.112370","article-title":"Antibody-gold nanoparticle bioconjugates for biosensors: synthesis, characterization and selected applications","volume":"165","author":"Zhang","year":"2020","journal-title":"Biosens. Bioelectron."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0590","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1002\/smll.201201068","article-title":"Negatively charged gold nanoparticles inhibit Alzheimer\u2019s amyloid-\u03b2 fibrillization, induce fibril dissociation, and mitigate neurotoxicity","volume":"8","author":"Liao","year":"2012","journal-title":"Small"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0595","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1039\/C7NR00699C","article-title":"The size-effect of gold nanoparticles and nanoclusters in the inhibition of amyloid-\u03b2 fibrillation","volume":"9","author":"Gao","year":"2017","journal-title":"Nanoscale"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0600","doi-asserted-by":"crossref","first-page":"4790","DOI":"10.1038\/s41467-020-18525-2","article-title":"Chiral gold nanoparticles enantioselectively rescue memory deficits in a mouse model of Alzheimer\u2019s disease","volume":"11","author":"Hou","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0605","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/nsr\/nwz215","article-title":"Au(23)(CR)(14) nanocluster restores fibril A\u03b2\u2019s unfolded state with abolished cytotoxicity and dissolves endogenous A\u03b2 plaques","volume":"7","author":"Zhang","year":"2020","journal-title":"Natl. Sci. Rev."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0610","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.bioelechem.2020.107643","article-title":"Immunosensor incorporating half-antibody fragment for electrochemical monitoring of amyloid-\u03b2 fibrils in artificial blood plasma","volume":"137","author":"Palla","year":"2021","journal-title":"Bioelectrochemistry"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0615","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.aca.2020.12.072","article-title":"Quantitative imaging of amyloid beta peptide (A\u03b2) in Alzheimer's brain tissue by laser ablation ICP-MS using gold nanoparticles as labels","volume":"1148","author":"Gao","year":"2021","journal-title":"Anal. Chim. Acta"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0620","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1097\/NEN.0b013e318225038c","article-title":"Targeting vascular amyloid in arterioles of Alzheimer disease transgenic mice with amyloid \u03b2 protein antibody-coated nanoparticles","volume":"70","author":"Poduslo","year":"2011","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0625","doi-asserted-by":"crossref","first-page":"349","DOI":"10.3233\/JAD-121171","article-title":"SPION-enhanced magnetic resonance imaging of Alzheimer\u2019s disease plaques in A\u03b2PP\/PS-1 transgenic mouse brain","volume":"34","author":"Sillerud","year":"2013","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0630","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nnano.2014.254","article-title":"Towards non-invasive diagnostic imaging of early-stage Alzheimer's disease","volume":"10","author":"Viola","year":"2015","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0635","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.neuro.2021.05.013","article-title":"PEGylated superparamagnetic iron oxide nanoparticles (SPIONs) ameliorate learning and memory deficit in a rat model of Alzheimer\u2019s disease: potential participation of STIMs","volume":"85","author":"Sanati","year":"2021","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0640","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1021\/cn300196n","article-title":"Influence of the physiochemical properties of superparamagnetic iron oxide nanoparticles on amyloid \u03b2 protein fibrillation in solution","volume":"4","author":"Mahmoudi","year":"2013","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0645","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.colsurfb.2016.04.041","article-title":"Cellular uptake of PLGA nanoparticles targeted with anti-amyloid and anti-transferrin receptor antibodies for Alzheimer's disease treatment","volume":"145","author":"Loureiro","year":"2016","journal-title":"Colloid Surf. B-Biointerfaces"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0650","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2304213120","article-title":"Nasal delivery of polymeric nanoDisc mobilizes a synergy of central and peripheral amyloid-beta clearance to treat Alzheimer's disease","volume":"120","author":"Zhang","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0655","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jconrel.2021.02.031","article-title":"Polymeric micelles in drug delivery: an insight of the techniques for their characterization and assessment in biorelevant conditions","volume":"332","author":"Ghezzi","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0660","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.jconrel.2023.06.038","article-title":"Purification processes of polymeric nanoparticles: how to improve their clinical translation?","volume":"360","author":"Tehrani","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0665","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jconrel.2023.01.067","article-title":"AAV vectors applied to the treatment of CNS disorders: clinical status and challenges","volume":"355","author":"Kang","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0670","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0675","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1371\/journal.pone.0057606","article-title":"Prophylaxis and treatment of Alzheimer\u2019s disease by delivery of an adeno-associated virus encoding a monoclonal antibody targeting the amyloid beta protein","volume":"8","author":"Shimada","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0680","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ymthe.2022.11.002","article-title":"AAV-mediated neuronal expression of an scFv antibody selective for Af3 oligomers protects synapses and rescues memory in Alzheimer models","volume":"31","author":"Selles","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0685","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.omtm.2023.101146","article-title":"A C1qTNF3 collagen domain fusion chaperones diverse secreted proteins and anti-A\u03b2 scFvs: applications for gene therapies","volume":"31","author":"Moore","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0690","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1371\/journal.pone.0226245","article-title":"Gene delivery of a modified antibody to A\u03b2 reduces progression of murine Alzheimer's disease","volume":"14","author":"Elmer","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0695","doi-asserted-by":"crossref","first-page":"1801362","DOI":"10.1002\/adma.201801362","article-title":"Overcoming the blood\u2013brain barrier: the role of nanomaterials in treating neurological diseases","volume":"30","author":"Furtado","year":"2018","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0700","doi-asserted-by":"crossref","first-page":"5151","DOI":"10.7150\/thno.85549","article-title":"PET imaging of focused-ultrasound enhanced delivery of AAVs into the murine brain","volume":"13","author":"Ajenjo","year":"2023","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0705","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/gt.2012.101","article-title":"Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates","volume":"20","author":"Gray","year":"2013","journal-title":"Gene Ther."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0710","doi-asserted-by":"crossref","DOI":"10.1038\/nn.4593","article-title":"Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems","volume":"20","author":"Chan","year":"2017","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0715","doi-asserted-by":"crossref","DOI":"10.1038\/s41551-022-00938-7","article-title":"Variants of the adeno-associated virus serotype 9 with enhanced penetration of the blood-brain barrier in rodents and primates","volume":"6","author":"Yao","year":"2022","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0720","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ymthe.2019.12.010","article-title":"AAV vector immunogenicity in humans: a long journey to successful gene transfer","volume":"28","author":"Verdera","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0725","doi-asserted-by":"crossref","first-page":"14262","DOI":"10.1021\/acsnano.0c03850","article-title":"Synthetically engineered adeno-associated virus for efficient, safe, and versatile gene therapy applications","volume":"14","author":"Lugin","year":"2020","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0730","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/nri3298","article-title":"HEVs, lymphatics and homeostatic immune cell trafficking in lymph nodes","volume":"12","author":"Girard","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0735","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113914","article-title":"Vaccine delivery systems toward lymph nodes","volume":"179","author":"Ding","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0740","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jconrel.2017.08.009","article-title":"Lymph node targeting strategies to improve vaccination efficacy","volume":"267","author":"Jiang","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0745","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s40820-023-01125-2","article-title":"Application of nano-delivery systems in lymph nodes for tumor immunotherapy","volume":"15","author":"Xia","year":"2023","journal-title":"Nano Lett."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0750","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1021\/acsnano.6b07343","article-title":"Immunological principles guiding the rational design of particles for vaccine delivery","volume":"11","author":"Gause","year":"2017","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0755","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.addr.2019.09.005","article-title":"Physical and chemical profiles of nanoparticles for lymphatic targeting","volume":"151-152","author":"Ke","year":"2019","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0760","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jconrel.2014.04.051","article-title":"Nano-chemotherapeutics: maximising lymphatic drug exposure to improve the treatment of lymph-metastatic cancers","volume":"193","author":"Ryan","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0765","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s12274-019-2301-3","article-title":"Critical size limit of biodegradable nanoparticles for enhanced lymph node trafficking and paracortex penetration","volume":"12","author":"Howard","year":"2019","journal-title":"Nano Res."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0770","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1002\/eji.200737984","article-title":"Nanoparticles target distinct dendritic cell populations according to their size","volume":"38","author":"Manolova","year":"2008","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0775","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1021\/mp060096p","article-title":"Type 1 and 2 immunity following vaccination is influenced by nanoparticle size: formulation of a model vaccine for respiratory syncytial virus","volume":"4","author":"Mottram","year":"2007","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0780","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1016\/j.apsb.2023.01.006","article-title":"Advanced subunit vaccine delivery technologies: from vaccine cascade obstacles to design strategies","volume":"13","author":"Hou","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0785","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20153781","article-title":"Effect of the hydrophilic-hydrophobic balance of antigen-loaded peptide nanofibers on their cellular uptake, cellular toxicity, and immune stimulatory properties","volume":"20","author":"Waku","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0790","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1039\/C4BM00140K","article-title":"The hydrophobic effect of nanoparticles composed of amphiphilic poly(\u03b3-glutamic acid) on the degradability of the encapsulated proteins","volume":"2","author":"Shima","year":"2014","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0795","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/nrd4608","article-title":"From sewer to saviour - targeting the lymphatic system to promote drug exposure and activity","volume":"14","author":"Trevaskis","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0800","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.jconrel.2022.12.022","article-title":"Protein-based nanocages for vaccine development","volume":"353","author":"Kim","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0805","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1093\/infdis\/jiy745","article-title":"New vaccine design and delivery technologies","volume":"219","author":"Kanekiyo","year":"2019","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0810","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jneumeth.2013.05.006","article-title":"Anti-A\u03b2 antibodies induced by A\u03b2-HBc virus-like particles prevent A\u03b2 aggregation and protect PC12 cells against toxicity of A\u03b21-40","volume":"218","author":"Feng","year":"2013","journal-title":"J. Neurosci. Methods"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0815","doi-asserted-by":"crossref","first-page":"6321","DOI":"10.1016\/j.vaccine.2006.05.059","article-title":"Virus and virus-like particle-based immunogens for Alzheimer's disease induce antibody responses against amyloid-beta without concomitant T cell responses","volume":"24","author":"Chackerian","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0820","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.4049\/jimmunol.177.4.2662","article-title":"Papillomavirus-like particles are an effective platform for amyloid-beta immunization in rabbits and transgenic mice","volume":"177","author":"Zamora","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0825","doi-asserted-by":"crossref","first-page":"7613","DOI":"10.4049\/jimmunol.0803366","article-title":"Vaccination with Abeta-displaying virus-like particles reduces soluble and insoluble cerebral Abeta and lowers plaque burden in APP transgenic mice","volume":"182","author":"Bach","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0830","doi-asserted-by":"crossref","first-page":"4450","DOI":"10.1016\/j.vaccine.2014.06.051","article-title":"A\u03b2-HBc virus-like particles immunization without additional adjuvant ameliorates the learning and memory and reduces A\u03b2 deposit in PDAPP mice","volume":"32","author":"Jin","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0835","article-title":"Engineered hepatitis B core virus-like particle carrier for precise and personalized Alzheimer\u2019s disease vaccine preparation via fixed-point coupling","volume":"19","author":"Ji","year":"2020","journal-title":"Appl. Mater. Today"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0840","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.biomaterials.2017.11.022","article-title":"Co-delivery of human cancer-testis antigens with adjuvant in protein nanoparticles induces higher cell-mediated immune responses","volume":"156","author":"Neek","year":"2018","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0845","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1021\/nn3052082","article-title":"Development of the vault particle as a platform technology","volume":"7","author":"Rome","year":"2013","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0850","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1038\/s41467-023-37417-9","article-title":"A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates","volume":"14","author":"Weidenbacher","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0855","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1371\/journal.pone.0152471","article-title":"An anti-\u03b2-amyloid vaccine for treating cognitive deficits in a mouse model of down syndrome","volume":"11","author":"Belichenko","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0860","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1073\/pnas.022627199","article-title":"A liposome-based therapeutic vaccine against \u03b2-amyloid plaques on the pancreas of transgenic NORBA mice","volume":"99","author":"Nicolau","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0865","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/adma.202207719","article-title":"A therapeutic nanovaccine that generates anti-amyloid antibodies and amyloid-specific regulatory T cells for Alzheimer\u2019s disease","volume":"35","author":"Jung","year":"2023","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0870","article-title":"Vaccine development to treat Alzheimer\u2019s disease neuropathology in APP\/PS1 transgenic mice","volume":"2012","author":"Carrera","year":"2012","journal-title":"Int. J. Alzheimers Dis."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0875","first-page":"119","article-title":"Immunocytochemical characterization of Alzheimer\u2019s disease hallmarks in APP\/PS1 transgenic mice treated with a new anti-amyloid-beta vaccine","volume":"2","author":"Carrera","year":"2013","journal-title":"Central Asian J. Glob. Health"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0880","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1208\/s12249-009-9279-1","article-title":"Amyloid-beta associated with chitosan nano-carrier has favorable immunogenicity and permeates the BBB","volume":"10","author":"Zhang","year":"2009","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0885","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.120597","article-title":"Polymeric nanoparticle vaccines to combat emerging and pandemic threats","volume":"268","author":"Wibowo","year":"2021","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0890","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/j.addr.2012.04.005","article-title":"Microneedles for drug and vaccine delivery","volume":"64","author":"Kim","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0895","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.114897","article-title":"Long-acting vaccine delivery systems","volume":"198","author":"Walvekar","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0900","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/s41551-020-00650-4","article-title":"Transdermal microneedles for the programmable burst release of multiple vaccine payloads","volume":"5","author":"Tran","year":"2021","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0905","doi-asserted-by":"crossref","first-page":"6279","DOI":"10.1002\/smll.201602344","article-title":"Injectable and pathogen-mimicking hydrogels for enhanced protective immunity against emerging and highly pathogenic influenza virus","volume":"12","author":"Noh","year":"2016","journal-title":"Small"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0910","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.addr.2020.12.008","article-title":"Non-viral COVID-19 vaccine delivery systems","volume":"169","author":"Park","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0915","doi-asserted-by":"crossref","first-page":"2107946","DOI":"10.1002\/adma.202107946","article-title":"Recent advances in delivery systems for genetic and other novel vaccines","volume":"34","author":"Huang","year":"2022","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0920","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.nbd.2020.105221","article-title":"Changes in the brain transcriptome after DNA A\u03b242 trimer immunization in a 3xTg-AD mouse model","volume":"148","author":"Lambracht-Washington","year":"2021","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0925","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jns.2007.05.012","article-title":"A\u03b242 gene vaccine prevents A\u03b242 deposition in brain of double transgenic mice","volume":"260","author":"Qu","year":"2007","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0930","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jns.2006.02.006","article-title":"A\u03b242 gene vaccination reduces brain amyloid plaque burden in transgenic mice","volume":"244","author":"Qu","year":"2006","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0935","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jalz.2013.12.003","article-title":"The MultiTEP platform-based Alzheimer\u2019s disease epitope vaccine activates a broad repertoire of T helper cells in nonhuman primates","volume":"10","author":"Davtyan","year":"2014","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0940","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2023.120564","article-title":"DNA A\u03b242 immunization via needle-less jet injection in mice and rabbits as potential immunotherapy for Alzheimer\u2019s disease","volume":"446","author":"Lambracht-Washington","year":"2023","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0945","doi-asserted-by":"crossref","first-page":"192","DOI":"10.4103\/2230-973X.167662","article-title":"Needle free injection technology: a complete insight","volume":"5","author":"Ravi","year":"2015","journal-title":"Int. J. Pharm. Investig."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0950","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1001\/jama.2009.1547","article-title":"DNA \u03b2-amyloid1-42 trimer immunization for Alzheimer disease in a wild-type mouse model","volume":"302","author":"Lambracht-Washington","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0955","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13195-018-0441-4","article-title":"Active full-length DNA A\u03b242 immunization in 3xTg-AD mice reduces not only amyloid deposition but also tau pathology","volume":"10","author":"Rosenberg","year":"2018","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0960","doi-asserted-by":"crossref","first-page":"6826","DOI":"10.7150\/thno.72685","article-title":"A sporadic Alzheimer\u2019s blood-brain barrier model for developing ultrasound-mediated delivery of aducanumab and anti-tau antibodies","volume":"12","author":"Wasielewska","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0965","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s10571-011-9680-7","article-title":"DNA immunization against amyloid beta 42 has high potential as safe therapy for Alzheimer\u2019s disease as it diminishes antigen-specific Th1 and Th17 cell proliferation","volume":"31","author":"Lambracht-Washington","year":"2011","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0970","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.clim.2013.05.016","article-title":"Effective DNA epitope chimeric vaccines for Alzheimer's disease using a toxin-derived carrier protein as a molecular adjuvant","volume":"149","author":"Yu","year":"2013","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0975","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0002124","article-title":"Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine - a novel immunotherapeutic strategy","volume":"3","author":"Movsesyan","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2024.09.012_bb0980","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jalz.2013.04.505","article-title":"Epitope-based DNA vaccine for Alzheimer\u2019s disease: translational study in macaques","volume":"10","author":"Evans","year":"2014","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0985","doi-asserted-by":"crossref","first-page":"483","DOI":"10.3233\/JAD-2004-6504","article-title":"Development of a safe oral A\u03b2 vaccine using recombinant adeno-associated virus vector for Alzheimer's disease","volume":"6","author":"Hara","year":"2004","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0990","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1096\/fj.06-7685com","article-title":"Oral vaccination with a viral vector containing A\u03b2 cDNA attenuates age-related A\u03b2 accumulation and memory deficits without causing inflammation in a mouse Alzheimer model","volume":"21","author":"Mouri","year":"2007","journal-title":"FASEB J."},{"key":"10.1016\/j.jconrel.2024.09.012_bb0995","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s12264-015-1546-4","article-title":"Autophagy is involved in oral rAAV\/A\u03b2 vaccine-induced A\u03b2 clearance in APP\/PS1 transgenic mice","volume":"31","author":"Wang","year":"2015","journal-title":"Neurosci. Bull."},{"key":"10.1016\/j.jconrel.2024.09.012_bb1000","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3389\/fimmu.2022.975803","article-title":"Immunogenicity and toxicity of AAV gene therapy","volume":"13","author":"Ertl","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2024.09.012_bb1005","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41573-021-00283-5","article-title":"mRNA vaccines for infectious diseases: principles, delivery and clinical translation","volume":"20","author":"Chaudhary","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2024.09.012_bb1010","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-021-03489-0","article-title":"Meningeal lymphatics affect microglia responses and anti-A\u03b2 immunotherapy","volume":"593","author":"Da Mesquita","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2024.09.012_bb1015","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/s43587-024-00630-2","article-title":"The path to next-generation disease-modifying immunomodulatory combination therapies in Alzheimer\u2019s disease","volume":"4","author":"Sarazin","year":"2024","journal-title":"Nat. Aging"},{"key":"10.1016\/j.jconrel.2024.09.012_bb1020","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24043895","article-title":"Alzheimer\u2019s disease: a brief history of immunotherapies targeting amyloid \u03b2","volume":"24","author":"Vogt","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2024.09.012_bb1025","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13024-023-00645-0","article-title":"Current views on meningeal lymphatics and immunity in aging and Alzheimer\u2019s disease","volume":"18","author":"Rego","year":"2023","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.jconrel.2024.09.012_bb1030","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/s41591-021-01382-x","article-title":"Biomarkers for neurodegenerative diseases","volume":"27","author":"Hansson","year":"2021","journal-title":"Nat. Med."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365924006229?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365924006229?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T22:38:06Z","timestamp":1778539086000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365924006229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":206,"alternative-id":["S0168365924006229"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.09.012","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Amyloid-\u03b2-targeting immunotherapies for Alzheimer's disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.09.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}